<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114371">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01945567</url>
  </required_header>
  <id_info>
    <org_study_id>2012-039</org_study_id>
    <nct_id>NCT01945567</nct_id>
  </id_info>
  <brief_title>Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor</brief_title>
  <official_title>Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Western Australia</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The posterior subthalamic area holds promise as a target region for deep brain stimulation
      in tremor and Parkinson's disease. Using the magnetic resonance-directed implantable guide
      tube surgical technique, subregions of the posterior subthalamic area can be individually
      targetted on a single electrode lead trajectory. The hypothesis is that the caudal zona
      incerta may provide improved control of movement disorder symptoms than the more commonly
      stimulated dorsal zona incerta.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomisation between two treatment locations each programmed up to 3 milliamps in amplitude
      for 3 months: (1) caudal zona incerta and (2) dorsal zona incerta. This 6-month-long
      randomised phase is followed by 6 months of unblinded individualised empirically optimised
      settings programmed by a neurologist. Each of the three treatment periods ends with a full
      clinical, functional and quality of life assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline United Parkinsons Disease Rating Scale Part III at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of first randomised crossover trial period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline United Parkinsons Disease Rating Scale Part III at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of second randomised crossover trial period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline United Parkinsons Disease Rating Scale Part III at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of non-randomised empirical deep brain stimulator programming period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Fahn Tolosa Marin tremor scale at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of first randomised crossover trial period for tremor patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Fahn Tolosa Marin tremor scale at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of second randomised crossover trial period for tremor patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Fahn Tolosa Marin tremor scale at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of empirical deep brain stimulator programming period for tremor patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline ON-OFF diary at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>For Parkinson's disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline ON-OFF diary at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>For Parkinson's disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline ON-OFF diary at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>For Parkinson's disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any adverse medical event from date of randomization until the date of first documented adverse event or date of death from any cause, whichever came first, assessed up to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Short form 36 at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of first randomised crossover period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Short form 36 at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of second randomised crossover period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Short form 36 at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of empirical deep brain stimulator programming period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Parkinsons Disease Quality of Life 39 at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of first randomised crossover period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Parkinsons Disease Quality of Life 39 at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of second randomised crossover period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Parkinsons Disease Quality of Life 39 at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of empirical deep brain stimulator programming period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline L-dopa equivalent dose at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of first randomised crossover period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline L-dopa equivalent dose at 6 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of second randomised crossover period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline L-dopa equivalent dose at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of empirical deep brain stimulator programming period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline neuropsychological battery at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of first randomised crossover period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline neuropsychological battery at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of second randomised crossover period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline neuropsychological battery at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of empirical deep brain stimulator programming period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline verbal fluency at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of first randomised crossover period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline verbal fluency at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of second randomised crossover period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline verbal fluency at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of empirical deep brain stimulator programming period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Mini-International Neuropsychiatric Interview Plus at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At end of first randomised crossover period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Mini-International Neuropsychiatric Interview Plus at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At end of second randomised crossover period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Mini-International Neuropsychiatric Interview Plus at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At end of empirical deep brain stimulator programming period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of first randomised crossover period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of second randomised crossover period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of empirical deep brain stimulator programming period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Abnormal Involuntary Movement Scale at 3 months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of first randomised crossover period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Abnormal Involuntary Movement Scale at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of second randomised crossover period for Parkinsons disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Abnormal Involuntary Movement Scale at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At end of empirical deep brain stimulator programming period for Parkinsons disease</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Tremor</condition>
  <arm_group>
    <arm_group_label>Dorsal zona incerta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 mA, 60 us, 130 Hz deep brain stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caudal zona incerta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 mA, 60 us, 130 Hz deep brain stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empirical deep brain stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empirical unblinded deep brain stimulation programming using any posterior subthalamic area electrode contact(s) and stimulation parameters to optimise clinical outcome.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Up to 3 mA, 60 us, 130 Hz deep brain stimulation</intervention_name>
    <arm_group_label>Dorsal zona incerta</arm_group_label>
    <arm_group_label>Caudal zona incerta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Empirical unblinded deep brain stimulation programming</intervention_name>
    <arm_group_label>Empirical deep brain stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medication-refractory tremor and/or Parkinson's disease as defined by UK Brain Bank
             criteria with either inadequate control of motor fluctuations or dyskinesia despite
             optimised medical therapy

        Exclusion Criteria:

          -  Significant cognitive, psychiatric and medical co-morbidities

          -  Dementia with mini mental state examination score of less than 25/30

          -  Limited life expectancy due to a co-morbid condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Lind, MBChB, FRACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Western Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Lind, MBChB, FRACS</last_name>
    <phone>+61 8 9346 2865</phone>
    <email>Christopher.Lind@health.wa.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Megan Thorburn, RN</last_name>
    <email>Megan.Thorburn@health.wa.gov.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.neurofinity.org</url>
    <description>Surgical NeuroDiscovery Group</description>
  </link>
  <link>
    <url>http://www.scgh.health.wa.gov.au/OurServices/Neurosurgery/index.html</url>
    <description>Neurosurgical Service of Western Australia, Sir Charles Gairdner Hospital</description>
  </link>
  <link>
    <url>http://www.surgery.uwa.edu.au/</url>
    <description>School of Surgery, University of Western Australia</description>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 17, 2013</lastchanged_date>
  <firstreceived_date>September 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Western Australia</investigator_affiliation>
    <investigator_full_name>Professor Christopher Lind</investigator_full_name>
    <investigator_title>Professor, School of Surgery</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Essential tremor</keyword>
  <keyword>Tremor</keyword>
  <keyword>Deep brain stimulation</keyword>
  <keyword>Posterior subthalamic area</keyword>
  <keyword>Zona incerta</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Tremor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
